OBJECTIVE: To evaluate the feasibility of the transperineal implementation of biocompatible balloon (Prospace) and the acute toxicity of high dose 3DCRT in patients with localized low risk prostate cancer.
MATRIALS AND METHODS: Between December 2011 and April 2012, fifteen patients were treated with external 3DCRT consisted of 76--78 Gy in 38--39 daily fractions (2.0 Gy/ fraction). Before 3DCRT, we placed the Prospace though the perineum by a minimally invasive procedure in the intermediate space between the rectum and the prostate. The primary study endpoint was the evaluation of acute toxicity according to the EORTC/RTOG radiation toxicity scale. Erectile function was evaluated with the IIEF-5 questionnaire. Rectosigmoidoscopy was performed at baseline, at the end of 3DCRT and 3 months thereafter in order to assess also the rectal toxicity according to Subjective-RectoSigmoid (S-RS) scale. The evaluation of pain related to Prospace implementation was done with the visual analogue score (VAS).
RESULTS: The acute toxicities were as follows: grade I GI toxicity in two patients and for GU toxicity, three patients with grade I of nocturia, four patients with grade I of frequency, two patients with grade I and two patients with grade II of dysouria. The mean score of rectal toxicity according to S-RS score was 1.8(+/-0.6). The mean VAS score related to Prospace was 1.4(+/-0.5). Erectile function was unchanged. The Prospace device was found stable in sequential CTs during irradiation.
CONCLUSIONS: The implementation of PROSPACE was feasible, while the acute radiation toxicity was low and comparable with IMRT techniques.
Written by:
Vassilis K, Theodoros K, Kalliopi P, John G, George M, Dimitris C, Ivelina B, Panagiotis P, Charalambos A, John K, Nikolaos K. Are you the author?
Reference: Radiat Oncol. 2013 Apr 8;8(1):82.
doi: 10.1186/1748-717X-8-82
PubMed Abstract
PMID: 23566526
UroToday.com Prostate Cancer Section
